A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact
Status:
Recruiting
Trial end date:
2021-12-30
Target enrollment:
Participant gender:
Summary
The purpose of this two-part Phase 2 study is to assess the safety, tolerability and efficacy
of aerosolized SF-RI 1 (AeroFact) when delivered via nCPAP at two different doses.